MedPath
HSA Approval

FLORINEF TABLET 0.1 mg

SIN10680P

FLORINEF TABLET 0.1 mg

FLORINEF TABLET 0.1 mg

January 20, 1999

DCH AURIGA SINGAPORE

DCH AURIGA SINGAPORE

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantDCH AURIGA SINGAPORE
Licence HolderDCH AURIGA SINGAPORE

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

**RECOMMENDED DOSAGE** Dosage depends on the severity of the disease and the response of the patient. The lowest possible dose should be used to control the condition being treated, and a reduction in dosage should be made (gradually) when possible. **Adrenocorticoid Insufficiency (chronic).** In Addison’s disease, the combination of **FLORINEF** with a glucocorticoid such as hydrocortisone or cortisone provides substitution therapy approximating normal adrenal activity. The usual dose for adults, adolescents, and elderly patients is one tablet (0.1 mg) of **FLORINEF** daily – range: one tablet (0.1 mg) three times a week to two tablets (0.2 mg) daily. If treatment-associated hypertension develops, the dose should be reduced to 0.05 mg daily. **FLORINEF** is preferably administered in conjunction with cortisone (10 mg to 37.5 mg daily in divided doses) or hydrocortisone (10 mg to 30 mg daily in divided doses). **Salt-losing Adrenogenital Syndrome** The recommended dosage for treating salt-losing adrenogenital syndrome is one tablet (0.1 mg) to two tablets (0.2 mg) of **FLORINEF** daily. Pediatric and Adolescent: One half tablet (0.05 mg) to one tablet (0.1 mg) daily.

ORAL

Medical Information

**INDICATIONS AND USAGE** **FLORINEF** is indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome.

**CONTRAINDICATIONS** Corticosteroids are contraindicated in patients with systemic fungal infections and in those with suspected or known hypersensitivity to fludrocortisone or any of the inactive ingredients.

H02AA02

fludrocortisone

Manufacturer Information

DCH AURIGA SINGAPORE

Haupt Pharma Amareg GmbH

Active Ingredients

FLUDROCORTISONE ACETATE

0.1 mg

Fludrocortisone

Documents

Package Inserts

Florinef Tablet PI.pdf

Approved: July 29, 2019

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

FLORINEF TABLET 0.1 mg - HSA Approval | MedPath